Striving to End Life-Threatening Bloodstream Infections
The Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) is a single use, extracorporeal pathogen-reducing blood filter used to reduce the level of pathogens in the bloodstream.
Revolutionary Treatment to Combat Bloodstream Infections
Seraph 100 was the first device with an indication to specifically reduce pathogens in the bloodstream in adjunction to antibiotic therapy. A long-awaited addition to conventional approaches to treat drug-resistant and drug-susceptible pathogens.
Safe, Early Intervention Option
An EU clinical safety trial reported no device- or treatment-related adverse events.1 In addition, multiple independent studies have demonstrated the Seraph 100’s safety and biocompatibility.2,3 Due to its broad-spectrum binding capability, rapid reduction of pathogens requires as little as one four-hour session and can be used as an early intervention prior to pathogen identification.
Pathogen Source Control
The binding properties of the Seraph 100 reduce pathogens from the bloodstream regardless of anti-infective medication resistance/super-resistance.
Our Technology
As a patient’s blood flows through the Seraph 100, it passes through a column of small beads with receptors that mimic those of the vascular endothelium that pathogens target when they invade the body. Many harmful substances are quickly captured and adsorbed onto the surface of the beads and are thereby subtracted from the bloodstream.
About Exthera Medical
ExThera Medical develops extracorporeal blood filtration devices, including the Seraph® 100 Microbind® Affinity Blood Filter for removing a broad range of harmful substances from the bloodstream of patients. ExThera Medical’s extracorporeal products have demonstrated life-saving capabilities in a wide range of critically ill patients suffering from severe infections.
With a growing body of outcome and health economic evidence from independent clinical studies, successful clinical use in the U.S. and EU for the treatment of bloodstream infections, and positive in vitro test results demonstrating removal of circulating tumor cells4, 5 the company is well-positioned to serve healthcare professionals and patients alike. Company headquarters is located in Martinez, California.
References
| 1. | Eden G, Schmidt J, Büttner S, et al. Safety and efficacy of the Seraph® 100 Microbind® Affinity Blood Filter to Remove Bacteria from the Blood Stream: Results of the First inHuman Study. Crit Care. 26, 181 (2022). Doi:10.1186/s13054-022-04044-7 |
| 2. | Chitty SA, Mobbs S, Rifkin BS, et al. A Multicenter Evaluation of the Seraph 100 MicrobindAffinity Blood Filter for the Treatment of Severe COVID-19. Crit Care Explor J. 2022; 4(4):1-11.DOI: 10.1097/CCE.0000000000000662 |
| 3. | Schmidt JJ, Borchina D, van’t Klooster M, et al. Interim Analysis of the COSA (COVID-19Patients Treated with the Seraph 100 Microbind Affinity Filter) Registry.Nephrol DialTransplant. 2022; 37(4):673-680. doi: 10.1093/ndt/gfab347 |
| 4. | Shishido SN, Suresh D et al.Determining the efficacy of ExThera Seraph100 blood filtrationin patients diagnosed with pancreatic cancer through the liquid biopsy.BJC Rep2, 47(2024). doi: 10.1038/s44276-024-00069-3. |
| 5. | Waldron R, Wang R, Shishido S et al. Selective removal of proteins and microvesicles exvivo from blood of pancreatic cancer patients using bioengineered adsorption filters.Cancer Letters, 2025; 614:217546. doi: 10.1016/j.canlet.2025.217546. |
ExThera Medical Corporation | 757 Arnold Drive | Suite B | Martinez, CA 94550
Tel: +1.925.839.2060 | Fax: +1.925.839.2075
© 2025 ExThera Medical
The Seraph 100 has been authorized by the U.S. FDA under an Emergency Use Authorization (EUA) to treat patients with COVID-19 infection. The Seraph 100 is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the Seraph 100 device under section 564(b) (1) of the Act, 21 U.S.C. § 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.
Seraph 100 is not currently available in the EU. MM00060 Rev A